Recurrence of Hepatitis B Infection in Liver Transplant Patients Receiving Long-Term Hepatitis B Immunoglobulin Prophylaxis

prevention of hepatitis b recurrence in liver transplant patients using oral antiviral therapy without long-term hepatitis b immunoglobulin

Prevention of Hepatitis B Recurrence in Liver Transplant Patients Using Oral Antiviral Therapy without Long-Term Hepatitis B Immunoglobulin

BACKGROUND Small studies have suggested that nucleos(t)ide analogue therapy (NAT) with reduced hepatitis B immunoglobulin (HBIG) duration may be efficacious in preventing post-liver transplantation (LT) HBV recurrence. OBJECTIVES This larger study evaluates the use of NAT with short term (< 6 mo) or no HBIG for prevention of post-LT HBV recurrence. PATIENTS AND METHODS All HBV patients unde...

The Study of Cerumen Hepatitis B Infection in Chronic Hepatitis B Patients by Real-Time PCR

Introduction: The hepatitis B is a viral infection that causes a big problem globally. About 2 billion people worldwide are infected and there are now about 400 million HBV-DNA carriers around the world. HBV infection is the ninth cause of death worldwide and infects about 350 million new cases each year in the world. HBV-DNA can be spotted in different body secretions and fluids, including se...

Is Hepatitis B Immunoglobulin Necessary in Prophylaxis of Hepatitis B Recurrence after Liver Transplantation? A Meta-Analysis

BACKGROUND & AIMS Application of nucleoside analogues and hepatitis B immunoglobulin (HBIG) has reduced hepatitis B virus (HBV) recurrence rate after liver transplantation (LT) dramatically. Recent data suggests therapy without HBIG is also effective. We sought to evaluate the necessity of HBIG in prophylaxis of HBV recurrence after LT. METHODS A meta-analysis was performed. PubMed/MEDLINE, W...

ymdd motif mutation profile among patients receiving liver transplant due to hepatitis b virus infection with long term lamivudine/immunoglobulin therapy

conclusions although the patients carrying m204i mutation were more likely to show lack of responses to lam therapy, lam replacing by other nucleoside/tide analogs plus hbig maybe still effective in decreasing hepatitis b recurrence after liver transplantation. however, it is suggested that drug resistance test should be considered by clinicians during therapeutic management to avoid the follow...